Research Updates
Cure JM is proud to offer grant funding for clinicians and researchers who are working to improve juvenile myositis care and advance research. Cure JM is also working diligently to find a cure for JM by working with scientists and doctors on new research every day.
Breaking Research News
With your financial support, Cure JM is proud to have funded Fionnuala McMorrow, a Postgraduate Research Student in the Department of Life Sciences at the University of Bath, to embark on a critical research project. Fionnuala’s team analyzed blood samples from the UK to investigate two specific biomarkers (anti-CCAR1 and anti-Sp4) recently identified in U.S. patients with JDM and related conditions.
The generous support of our community has been instrumental in funding groundbreaking research this year, led by Dr. Christian Lood at the University of Washington and Cure JM’s Center of Excellence at Seattle Children’s Hospital. Dr. Lood’s team has identified calcified mitochondria in the muscle tissue of JDM patients with calcinosis – a finding that sheds new light on understanding JDM.
Cabaletta Bio Presents Promising Early Data for CAR-T in Myositis
Exciting news from the European Congress of Rheumatology (EULAR) 2024 last month in Vienna, Austria! Cure JM partner Cabaletta Bio, presented encouraging results from their CAR-T cell therapy, CABA-201, in treating myositis.
Initial data from the first two patients dosed with CABA-201 showed positive signs in terms of safety, clinical response, and biological markers. Cabaletta believes this data validates the potential of CABA-201 to “reset the immune system” in patients with myositis and other autoimmune diseases.
The Chan Zuckerberg Initiative has awarded Cure JM and a consortium of Cure JM-funded researchers a coveted $2 million rare disease research grant to identify new biomarkers in JM and improve precise, personalized care through the identification of cell-to-cell interactions that drive inflammation in juvenile myositis.
A clinical trial treating patients with juvenile myositis with the drug abatacept resulted in lower disease activity and clinically significant responses in most patients.
Current Clinical Trials
Help researchers find the cause and a cure for JM by volunteering for these important studies. Please contact info@curejm.org for further information.
Grants & Funding
Cure JM offers grant funding for clinicians and researchers who are working to improve juvenile myositis care and advance research.
